Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Short term Debt (2016 - 2025)

Angiodynamics (ANGO) has disclosed Short term Debt for 14 consecutive years, with $5.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Short term Debt fell 47.37% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Feb 2025, down 47.37%, and an annual FY2024 reading of $4.7 million, down 67.97% over the prior year.
  • Short term Debt was $5.0 million for Q1 2025 at Angiodynamics, up from $5.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $14.8 million in Q2 2023 and bottomed at $4.7 million in Q2 2024.
  • Average Short term Debt over 4 years is $7.9 million, with a median of $8.8 million recorded in 2022.
  • The sharpest move saw Short term Debt soared 68.06% in 2023, then plummeted 67.97% in 2024.
  • Year by year, Short term Debt stood at $9.8 million in 2022, then fell by 3.82% to $9.4 million in 2023, then crashed by 47.16% to $5.0 million in 2024, then rose by 0.81% to $5.0 million in 2025.
  • Business Quant data shows Short term Debt for ANGO at $5.0 million in Q1 2025, $5.0 million in Q4 2024, and $4.8 million in Q3 2024.